Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos

Items tag "zebrafish"


Companies news
12/12/2016
ROJA 
ZeClinics receives €1.87M funding in the latest round of the Horizon2020 SME Instrument Phase 2 ZeClinics
ZeClinics receives €1.87M funding in the latest round of the Horizon2020 SME Instrument Phase 2 ZeClinics has been granted with the SME Instrument Phase 2 within the European Union framework Horizon 2020, category "Supporting Innovative SMEs in the healthcare biotechnology sector".
  View more
05/02/2012
ROJA 
Biobide demonstrates that the “Automated tyrosine kinase cardiotoxicity assay in zebrafish” is highly predictive and provides complementary data to other in vitro assays BIOBIDE
Biobide demonstrates that the “Automated tyrosine kinase cardiotoxicity assay in zebrafish” is highly predictive and provides complementary data to other in vitro assays Biobide in collaboration with AB Sciences have demonstrated that the zebrafish Cardiotox Assay is a good tool to predict cardiotoxicity in humans and can complement in vitro assays hERG channel Inhibition, human cardiomyocytes (hCM); ROS production by treated cardiomyocytes (hROS).
  View more
01/23/2012
ROJA 
The results of BIOBIDE´s participation in the European FP7 project (ZF-Cancer) have been published in Oncoge. BIOBIDE
The results of BIOBIDE´s participation in the European FP7 project (ZF-Cancer) have been published in Oncoge. The results obtained by Biobide in collaboration with the Center for Regenerative Medicine in Barcelona, the Biotech Galapagos and the Salk Institute for Biological Studies (USA) , have been published in the prestigious journal ONCOGENE.
  View more
11/02/2011
ROJA 
Zebrafish used as research model to test drug efficacy against cancer BIOBIDE
Zebrafish used as research model to test drug efficacy against cancer The biotechnology company BIOBIDE, part of the Genetrix Group, has developed a method using the zebrafish animal model to measure the pharmacological efficacy of new moleculesin the research stage for treating cancer.
  View more
09/05/2011
BLANCA  ROJA 
BIOBIDE has been selected to present in the “European Cancer Cluster partnering” (ECCP) that will be celebrated in Toulouse, France from September 14th to 16th BIOBIDE
BIOBIDE has been selected to present in the “European Cancer Cluster partnering” (ECCP) that will be celebrated in Toulouse, France from September 14th to 16th BIOBIDE has been selected to present in the “European Cancer Cluster partnering” (ECCP) that will be celebrated in Toulouse, France from September 14th to 16th
  View more
07/18/2011
BLANCA  ROJA  VERDE 
BIOBIDE is going to participate in the “World Drug Targets Summit” that will be celebrated in Cambridge, Massachusetts from July 20th to 21st BIOBIDE
BIOBIDE is going to participate in the “World Drug Targets Summit” that will be celebrated in Cambridge, Massachusetts from July 20th to 21st Carles Callol (Scientific Director of BIOBIDE) is attending to The World Drug Targets Summit. This event is a cutting edge meeting that provides a great blend of senior executives and scientists from pharma/biotech companies and academia in the field to discuss different target identification and validation strategies.
  View more
07/14/2011
BLANCA  ROJA  VERDE 
Successful renewal of the Certificate of Good Laboratory Practice (GLP) BIOBIDE
Successful renewal of the Certificate of Good Laboratory Practice (GLP) BIOBIDE obtained the renewal of the Certificate of Good Laboratory Practice (GLP) (obtained for the first time in August 2009).
  View more
06/30/2011
BLANCA  ROJA 
Biobide Scientific Director participated in the "High Content Screening Workshop" organized by CNIC. BIOBIDE
Biobide Scientific Director participated in the Biobide Scientific Director participated in the "High Content Screening Workshop" organized by CNIC.
  View more